ArticleReproductive health2026
Postpartum contraception receipt among Oregon Medicaid-funded births with stimulant and substance use disorder.
Article in Reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo compare postpartum contraceptive receipt among (i) Medicaid beneficiaries with stimulant-related substance use disorder (SUD) to those without SUD; and (ii) Medicaid beneficiaries with other SUD to those without SUD.
methodsThis was a retrospective cohort study of birthing events using Oregon's linked Medicaid claims and vital statistics data 2012-2019 (N = 141,479). We described demographic characteristics, birth outcomes, and substances used, and compared rates of contraception receipt (i) immediately postpartum (IPP), (ii) within 60 days postpartum excluding IPP, and (iii) within 60 days postpartum including IPP.
resultsPrevalence of stimulant-related and other SUD diagnosis was 3.8% and 9.4%, respectively. After adjusting for demographic and clinical factors, contraception receipt within 60 days postpartum including IPP and contraception receipt IPP were greater for birth events with a stimulant-related SUD compared to birth events without SUD (adjusted relative risk [aRR], 60-days postpartum including IPP: 1.12, 95% CI: 1.07-1.17; aRR, IPP: 1.32, 95% CI: 1.24-1.40). Adjusted rates of contraception receipt were also elevated for birth events with other SUD compared to birth events with no SUD (aRR, 60-days postpartum including IPP: 1.12, 95% CI: 1.09-1.15; aRR, IPP: 1.21, 95% CI: 1.16-1.26; aRR, 60-days postpartum excluding IPP: 1.09, 95% CI: 1.06-1.13).
conclusionsBirthing people enrolled in Medicaid who misused stimulants were more likely than those without SUD, controlling for relevant factors, to receive postpartum contraception within 60 days due to elevated contraception receipt during the IPP period. Further research may examine whether these findings can be replicated outside of Oregon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.